Ultime notizie per BioAtla (NASDAQ:BCAB) Azioni

BioAtla

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

BioAtla Inc

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Outperform and raises the price target from $352 to $359.

News

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Outperform on Willis Towers Watson, Raises Price Target to $359

WIIM

PRAA

PRA Group shares are trading higher after the company reported better-than-expected Q3 financial results. Additionally, Truist Securities maintained a Buy rating on the stock and raised its price target from $28 to $31.

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith reiterates Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) with a Outperform and raises the price target from $82 to $90.

Reiteration

ROOT

Keefe, Bruyette & Woods Reiterates Outperform on Root, Raises Price Target to $90

CENX

Century Aluminum shares are trading higher after the company reported better-than-expected Q3 financial results and B.Riley Securities raised its price target on the stock from $22 to $24.

JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and lowers the price target from $510 to $503.

VRTX

JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $503

Diversified Healthcare Trust shares are trading lower after the company reported worse-than-expected Q3 financial results.

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) with a Market Perform and lowers the price target from $210 to $198.

Keefe, Bruyette & Woods Maintains Market Perform on Meritage Homes, Lowers Price Target to $198

JP Morgan analyst Peter Peng maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Overweight and lowers the price target from $150 to $135.

SLAB

JP Morgan Maintains Overweight on Silicon Laboratories, Lowers Price Target to $135

RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and raises the price target from $252 to $254.

ILMN

RBC Capital Maintains Outperform on Illumina, Raises Price Target to $254

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) with a Market Perform and lowers the price target from $6 to $5.

Keefe, Bruyette & Woods Maintains Market Perform on Marqeta, Lowers Price Target to $5

SANA

Sana Biotechnology shares are trading lower after JMP Securities downgraded the stock from Market Outperform to Market Perform. Also, HC Wainwright & Co. lowered its price target from $11 to $8.

JP Morgan analyst Samik Chatterjee maintains Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with a Underweight and lowers the price target from $34 to $32.

JP Morgan Maintains Underweight on Sensata Technologies, Lowers Price Target to $32

Keefe, Bruyette &amp; Woods analyst Vasundhara Govil maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Outperform and raises the price target from $97 to $102.

Keefe, Bruyette & Woods Maintains Outperform on Fidelity National Info, Raises Price Target to $102

DXPE

DXP Enterprises shares are trading higher after the company reported better-than-expected Q3 financial results.

The U.S. services sector's economic momentum is firing at all cylinders, with business activity in October reaching its strongest level <a href="https://www.benzinga.com/news/econ-s">in over two years.</a>
According to the Institute for Supply Management, the Services PMI surged to 56% in October 2024, up from 54.9% in September, defying expectations of a dip to 53.8%.
This result marks the fastest pace of expansion in the U.S. services sector since August 2022. The ISM Services PMI has shown growth in 20 of the past 22 months since January 2023, with October's reading standing 3.7 percentage points above the 2024 average of 52.3%.
&#8220;The increase in the Services PMI&nbsp;in October was driven by boosts of more than 4 percentage points for both the Employment and Supplier Deliveries indexes. The Business Activity and New Orders indexes both dropped by at least 2 percentage points. Each of the four subindexes are now above their averages for 2024,&#8221; stated Steve Miller, chair of the ISM Services Business Survey Committee, said.
<h3 class="wp-block-heading">ISM Services PMI For October: Key Highlights</h3>
<ul>
<li>The subindex for Business Activity eased from 59.9% to 57.2% in October.</li>
<li>The subindex for New Orders eased from 59.4% to 57.4% in October. </li>
<li>The subindex for Prices eased from 59.4% to 58.1%. </li>
<li>The subindex for Employment rose from 48.1% to 53%, well above the expected 48%. The outcome marked the highest level in employment index since September 2023. </li>
</ul>
&#8220;Concerns over political uncertainty were again more prevalent than the previous month. Impacts from hurricanes and ports labor turbulence were mentioned frequently, although several panelists mentioned that the longshoremen's strike had less of an impact than feared due to its short duration,&#8221; Miller added. 
<h3 class="wp-block-heading">Market Reactions</h3>
On Tuesday, U.S. stocks rebounded as investors reacted positively to the latest ISM Services PMI data, alleviating earlier political concerns as Americans headed to the polls to elect the 47th president.
The S&amp;P 500, represented by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), rose 0.8%. The tech-heavy Nasdaq 100, tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), rallied nearly 1%, while the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) edged 0.6% higher.
Yields on 10-year Treasury bonds rose 7 basis points to 4.36%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 0.5%. 
The U.S. dollar index — as tracked by the  Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) — weakened 0.5%.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/11/41722178/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan">If Trump And Republicans Sweep, Dollar May Climb 7% — But Harris Win Could Bring 5% Drop, Says JPMorgan</a></li>
</ul>
Image: Shutterstock

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Treasuries

Econ #s

Economics

ETFs

SPDR Dow Jones Industrial Average ETF Trust

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

US Services Sector Gauge Rises More Than Expected To Over 2-Year Highs As Employment Index Defies Hurricane Shocks

Cushman & Wakefield shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

REAL

The RealReal shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 revenue guidance above estimates.

JP Morgan analyst Tien-Tsin Huang maintains Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) with a Neutral and lowers the price target from $6 to $5.

JP Morgan Maintains Neutral on Marqeta, Lowers Price Target to $5

Keefe, Bruyette &amp; Woods analyst Aidan Hall reiterates Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Underperform and lowers the price target from $20 to $19.

Keefe, Bruyette & Woods Reiterates Underperform on Franklin Resources, Lowers Price Target to $19

RBC Capital analyst Luca Issi maintains Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) with a Sector Perform and lowers the price target from $12 to $10.

ADVM

RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $10

BioAtla GAAP EPS of -$0.44 in-line

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

BioAtla (BCAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni Benjamin from JMP Secur...

Reni Benjamin's Buy Rating for BioAtla: Strong Pipeline and Financial Health Signal Upside Potential

Michael Burry's Scion Asset sheds Safe Bulkers, adds Hudson Pacific, others in Q2

Justin Zelin, an analyst from BTIG, reiterated the Buy rating on BioAtla (BCAB – Research Report). The associated price target was raised to $13.00...

Buy Rating for BioAtla: Promising Pipeline and Strategic Partnerships Fuel Optimistic Outlook

Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on BioAtla (BCAB – Research Report), retaining the price target of $5.00. Reni Benj...

Buy Rating Affirmed for BioAtla on Strong Clinical Data and Solid Financial Positioning

BioAtla out-licenses BA3362 to Context Therapeutics

Analyst Justin Zelin of BTIG maintained a Buy rating on BioAtla (BCAB – Research Report), retaining the price target of $13.00. Justin Zelin has gi...

Buy Rating Affirmed for BioAtla Amidst Strategic Collaborations and Promising Clinical Catalysts

BioAtla: Numerous Catalysts Coming In Q4

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

BABA

BCAB

BIDU

CNTX

OLPX

PHYS

SBLK

Health Care

Press Releases

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024

Earnings

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Comments

BioAtla

Notizie

Ultime notizie per BioAtla (NASDAQ:BCAB) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO